To evaluate the in vivo prophylaxis and therapeutic efficacy of G7-Fc, we administered the G7-Fc into K18-ACE2 transgenic mice and BALB/c mice either before or after infection of XBB.1 (Fig. 3a). The gene discussed is ACE2; the disease is infection.